Kinnate BioPharma Inc.(KNTE)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KNTE Kinnate BioPharma Inc.

停牌 04-02 16:00:00 EDT

2.65

+0.00

0.00%

最高2.65	最低2.65	成交量0.00
今开2.65	昨收2.65	日振幅0.00%
总市值1.25亿	流通市值6,024万	总股本4,723万
成交额746.65万	换手率0.00%	流通股本2,273万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"KNTE","market":"US","secType":"STK","nameCN":"Kinnate BioPharma Inc.","latestPrice":2.65,"timestamp":1712088000000,"preClose":2.65,"halted":3,"volume":0,"delay":0,"floatShares":22730609,"shares":47225312,"eps":-2.42,"marketStatus":"停牌","marketStatusCode":7,"change":0,"latestTime":"04-02 16:00:00 EDT","open":2.65,"high":2.65,"low":2.65,"amount":7466452.157226,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.42,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1606971600000,"adjPreClose":2.65,"volumeRatio":0},"requestUrl":"/m/hq/s/KNTE","defaultTab":"news","newsList":[{"id":"2421878694","title":"Kinnate Biopharma Inc    预计每股亏损 44 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2421878694","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2421878694?lang=zh_cn&edition=full","pubTime":"2024-03-23 05:04","pubTimestamp":1711141452,"startTime":"0","endTime":"0","summary":"   * Kinnate Biopharma Inc    预计在3月25日公布截至2023年12月31日的财报时，季度营收将没有变化(预计)。*    * LSEG分析师对Kinnate Biopharma Inc的平均预期是每股亏损44美分。* 华尔街对 Kinnate Biopharma Inc 的 12 个月目标价中位数为 2.50 美元，低于其上次收盘价 2.65 美元。3月22日 - 以前季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNTE"],"gpt_icon":0},{"id":"2419353011","title":"Kinnate Biopharma Inc    预计每股亏损 44 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2419353011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2419353011?lang=zh_cn&edition=full","pubTime":"2024-03-16 05:25","pubTimestamp":1710537921,"startTime":"0","endTime":"0","summary":"   * Kinnate Biopharma Inc    预计在3月18日公布截至2023年12月31日的财报时，季度收入将没有变化(预计)。*    * LSEG的分析师平均预计Kinnate Biopharma Inc每股亏损44美分。* 华尔街对 Kinnate Biopharma Inc 的 12 个月目标价中位数为 2.50 美元，低于其最新收盘价 2.53 美元。3月15日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNTE"],"gpt_icon":0},{"id":"2418315094","title":"Kinnate Biopharma Inc    预计每股亏损 44 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2418315094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2418315094?lang=zh_cn&edition=full","pubTime":"2024-03-12 04:51","pubTimestamp":1710190267,"startTime":"0","endTime":"0","summary":"   * Kinnate Biopharma Inc    预计在3月13日公布截至2023年12月31日的财报时，季度收入将没有变化(预计)。*    * LSEG的分析师平均预计Kinnate Biopharma Inc每股亏损44美分。* 华尔街对 Kinnate Biopharma Inc 的 12 个月目标价中位数为 2.50 美元，低于其上次收盘价 2.58 美元。3月11日 - 以前季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNTE"],"gpt_icon":0},{"id":"2416237611","title":"Kinnate Biopharma Inc.向皮尔法伯集团出售其在研泛 RAF 抑制剂 exarafenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2416237611","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2416237611?lang=zh_cn&edition=full","pubTime":"2024-03-04 23:05","pubTimestamp":1709564700,"startTime":"0","endTime":"0","summary":"Kinnate已与皮尔法伯集团就 exarafenib 和其他泛 RAF 计划资产的全球权利签订了一项资产购买协 。此次交易是为了进一步推进 Kinnate 此前宣布的战略替代方案寻求。旧金山、圣迭戈和卡斯特里（法国）2024年3月4日 /美通社/ --Kinnate Biopharma Inc.，一家临床阶段精准肿瘤学公司，与全球肿瘤公司Pierre Fabre Médicament, SA今天宣布，根据双方签订的APA 协议，双方同意出售公司的在研泛RAF 抑制剂exarafenib 及其他泛RAF 项目资产。Kinnate 的exarafenib 和其他泛RAF 项目资产的增加是对我们现有的BRAF 和MEK 抑制剂组合的补充。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4349520_ZH49520_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","KNTE"],"gpt_icon":0},{"id":"2416649487","title":"BUZZ-向皮埃尔-法布尔出售癌症疗法后，Kinnate Bio 公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2416649487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2416649487?lang=zh_cn&edition=full","pubTime":"2024-03-01 22:40","pubTimestamp":1709304042,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月1日 - ** 药物开发商Kinnate Biopharma   股价上涨5.1%至2.60美元 ** 该公司将 (link) 其名为 exarafenib 的实验性癌症疗法出售给了法国的 Pierre Fabre Médicament，售价高达 3100万美元。** 该疗法正在进行早期和早中期试验** 交易完成后，KNTE 将获得 50 万美元，并在达到某些里程碑后获得 3050 万美元。** 股价在过去 12 个月中下跌了 50.8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BUZZ","KNTE"],"gpt_icon":0},{"id":"2416649095","title":"Kinnate Biopharma Inc.盘中异动 早盘股价大涨6.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416649095","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2416649095?lang=zh_cn&edition=full","pubTime":"2024-03-01 22:31","pubTimestamp":1709303516,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日22时31分，Kinnate Biopharma Inc.股票出现波动，股价急速上涨6.47%。截至发稿，该股报2.63美元/股，成交量29.7406万股，换手率0.63%，振幅1.21%。Kinnate Biopharma Inc.股票所在的生物技术行业中，整体涨幅为0.86%。Kinnate Biopharma Inc.公司简介：Kinnate Biopharma Inc 是一家临床阶段的精准肿瘤学公司，专注于发现、设计和开发用于难以治疗的基因组定义癌症的小分子激酶抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030122315687d7ecb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030122315687d7ecb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KNTE"],"gpt_icon":0},{"id":"2411566281","title":"嗡嗡声--美国股票走势-Super Micro Computer、Kinsale Capital、Kinnate Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2411566281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2411566281?lang=zh_cn&edition=full","pubTime":"2024-02-16 23:53","pubTimestamp":1708098808,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      2月16日 - 周五，华尔街主要股指走低，此前一份热度高于预期的生产者物价报告打压了市场对美国联邦储备委员会  即将降息的猜测。美东时间10:31，道琼斯工业平均指数  下跌0.27%，报38,669.2点。标准普尔500指数  下跌0.39%，报5,010.17点；纳斯达克综合指数  下跌0.75%，报15,787.267点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LAD","BK4084","THS","BK4222","DASH","MSTR","PPL","KNSL","DNLI","TQQQ","TOST",".SPX","GE","BK4507","LU2249611893.SGD","BK4528","G","SRPT","HTOO","AMAT","BK4108","KNTE","PSQ","HRT","BE","QID","LU2023250504.SGD","QLD",".IXIC","AN","CTSH","SQQQ","RIOT","LU1861558580.USD","TTD","PAG","LU0868494617.USD","LU2468319806.SGD","SMCI","COIN","EPAM","ABG","QQQ","DLR","NQmain","LLY","ROKU","MNQmain","BK4523"],"gpt_icon":0},{"id":"2411661272","title":"BUZZ-Kinnate 生物制药公司被 XOMA 公司联合收购，股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2411661272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2411661272?lang=zh_cn&edition=full","pubTime":"2024-02-16 23:27","pubTimestamp":1708097245,"startTime":"0","endTime":"0","summary":"    2月16日 - ** 药物开发商Kinnate Biopharma   股价上涨11.9%至2.5美元 ** 该公司在  签订合并协议，将被生物技术公司 Xoma Corp    收购 ** XOMA 股价下跌 3.1%，报 21.50 美元** XOMA 将以每股约 2.34 美元 的现金和每股不超过25 美分的额外现金收购该公司** 根据交易，KNTE 的股东还有资格获得或有价值权，即在交易完成后一年内完成的任何 KNTE 候选药物的外部许可或销售净收益的 85%。** 预计交易将于 4 月完成** 交易完成后，KNTE 将与 XOMA 的一个部门合并 ** 包括当日涨幅在内，KNTE 在过去 12 个月中下跌了 63.5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","XOMA","BK4139","KNTE"],"gpt_icon":0},{"id":"2411561666","title":"Kinnate Biopharma Inc盘中异动 早盘急速上涨10.13%报2.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411561666","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2411561666?lang=zh_cn&edition=full","pubTime":"2024-02-16 22:31","pubTimestamp":1708093899,"startTime":"0","endTime":"0","summary":"北京时间2024年02月16日22时31分，Kinnate Biopharma Inc股票出现异动，股价大幅拉升10.13%。截至发稿，该股报2.50美元/股，成交量23.7497万股，换手率0.50%，振幅2.20%。Kinnate Biopharma Inc股票所在的生物技术行业中，整体跌幅为0.01%。Kinnate Biopharma Inc公司简介：Kinnate Biopharma Inc 是一家临床阶段的精准肿瘤学公司，专注于发现、设计和开发用于难以治疗的基因组定义癌症的小分子激酶抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021622313987975188&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021622313987975188&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNTE","BK4139"],"gpt_icon":0},{"id":"2402223705","title":"Kinnate Biopharma Inc盘中异动 股价大跌5.12%报2.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2402223705","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2402223705?lang=zh_cn&edition=full","pubTime":"2024-01-12 23:15","pubTimestamp":1705072544,"startTime":"0","endTime":"0","summary":"北京时间2024年01月12日23时15分，Kinnate Biopharma Inc股票出现异动，股价急速下挫5.12%。截至发稿，该股报2.41美元/股，成交量7.3406万股，换手率0.16%，振幅5.51%。Kinnate Biopharma Inc股票所在的生物技术行业中，整体涨幅为0.86%。Kinnate Biopharma Inc公司简介：Kinnate Biopharma Inc 是一家临床阶段的精准肿瘤学公司，专注于发现、设计和开发用于难以治疗的基因组定义癌症的小分子激酶抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024011223154487e652b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024011223154487e652b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KNTE"],"gpt_icon":0},{"id":"2402936419","title":"Kinnate Biopharma Inc盘中异动 下午盘股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2402936419","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2402936419?lang=zh_cn&edition=full","pubTime":"2024-01-09 02:37","pubTimestamp":1704739057,"startTime":"0","endTime":"0","summary":"北京时间2024年01月09日02时37分，Kinnate Biopharma Inc股票出现异动，股价大幅上涨5.19%。截至发稿，该股报2.54美元/股，成交量13.8619万股，换手率0.29%，振幅8.25%。Kinnate Biopharma Inc股票所在的生物技术行业中，整体跌幅为0.50%。Kinnate Biopharma Inc公司简介：Kinnate Biopharma Inc 是一家临床阶段的精准肿瘤学公司，专注于发现、设计和开发用于难以治疗的基因组定义癌症的小分子激酶抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240109023738861c935c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240109023738861c935c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNTE","BK4139"],"gpt_icon":0},{"id":"2400869113","title":"Kinnate Biopharma Inc盘中异动 股价大涨5.06%报2.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2400869113","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2400869113?lang=zh_cn&edition=full","pubTime":"2024-01-02 23:17","pubTimestamp":1704208648,"startTime":"0","endTime":"0","summary":"北京时间2024年01月02日23时17分，Kinnate Biopharma Inc股票出现异动，股价急速上涨5.06%。截至发稿，该股报2.49美元/股，成交量3.2784万股，换手率0.07%，振幅5.90%。Kinnate Biopharma Inc股票所在的生物技术行业中，整体涨幅为1.08%。Kinnate Biopharma Inc公司简介：Kinnate Biopharma Inc 是一家临床阶段的精准肿瘤学公司，专注于发现、设计和开发用于难以治疗的基因组定义癌症的小分子激酶抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401022317287a37dc6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401022317287a37dc6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KNTE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kinnate.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0.1522},{"period":"ytd","weight":0.1181}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kinnate Biopharma Inc.是一家生物制药公司，致力于发现和开发针对难以治疗的基因组定义的癌症的小分子激酶抑制剂。该公司的使命是通过为服务不足的人群开发产品来扩大靶向治疗的范围。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.08035},{"month":2,"riseRate":0.5,"avgChangeRate":-0.132211},{"month":3,"riseRate":0.75,"avgChangeRate":0.160008},{"month":4,"riseRate":0,"avgChangeRate":-0.268707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.212663},{"month":6,"riseRate":0.333333,"avgChangeRate":0.094765},{"month":7,"riseRate":0,"avgChangeRate":-0.081431},{"month":8,"riseRate":0.666667,"avgChangeRate":0.043045},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.168745},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.156375},{"month":11,"riseRate":0.333333,"avgChangeRate":0.275034},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.099619}],"exchange":"NASDAQ","name":"Kinnate BioPharma Inc.","nameEN":"Kinnate BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kinnate BioPharma Inc.(KNTE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kinnate BioPharma Inc.(KNTE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kinnate BioPharma Inc.,KNTE,Kinnate BioPharma Inc.股票,Kinnate BioPharma Inc.股票老虎,Kinnate BioPharma Inc.股票老虎国际,Kinnate BioPharma Inc.行情,Kinnate BioPharma Inc.股票行情,Kinnate BioPharma Inc.股价,Kinnate BioPharma Inc.股市,Kinnate BioPharma Inc.股票价格,Kinnate BioPharma Inc.股票交易,Kinnate BioPharma Inc.股票购买,Kinnate BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kinnate BioPharma Inc.(KNTE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kinnate BioPharma Inc.(KNTE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况